547 related articles for article (PubMed ID: 9317066)
1. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole: therapy of choice in intellectually disabled children.
Böhmer CJ; Niezen-de Boer RC; Klinkenberg-Knol EC; Meuwissen SG
Arch Pediatr Adolesc Med; 1998 Nov; 152(11):1113-8. PubMed ID: 9811290
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Festen HP; Schenk E; Tan G; Snel P; Nelis F
Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Schenk BE; Kuipers EJ; Klinkenberg-Knol EC; Eskes SA; Meuwissen SG
Am J Gastroenterol; 1999 Apr; 94(4):884-7. PubMed ID: 10201451
[TBL] [Abstract][Full Text] [Related]
6. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
[TBL] [Abstract][Full Text] [Related]
8. Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring.
Ladas SD; Tassios PS; Raptis SA
Am J Gastroenterol; 2000 Feb; 95(2):374-80. PubMed ID: 10685738
[TBL] [Abstract][Full Text] [Related]
9. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
10. Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD.
Katz PO
Rev Gastroenterol Disord; 2006; 6(3):136-45. PubMed ID: 16957654
[TBL] [Abstract][Full Text] [Related]
11. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy.
Katzka DA; Paoletti V; Leite L; Castell DO
Am J Gastroenterol; 1996 Oct; 91(10):2110-3. PubMed ID: 8855731
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy of gastroesophageal reflux disease patients with omeprazole.
Tepes B; Stabuc B; Kocijancic B; Ivanusa M
Hepatogastroenterology; 2009; 56(89):67-74. PubMed ID: 19453031
[TBL] [Abstract][Full Text] [Related]
13. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of gastroesophageal reflux disease in institutionalized intellectually disabled individuals.
Böhmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Devillé WL; Nadorp JH; Meuwissen SG
Am J Gastroenterol; 1999 Mar; 94(3):804-10. PubMed ID: 10086670
[TBL] [Abstract][Full Text] [Related]
16. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
17. [Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report].
Córdova-Villalobos JA; Ramírez-Barba EJ; Ramírez-Covarrubias JC
Rev Gastroenterol Mex; 1996; 61(4):306-9. PubMed ID: 9072780
[TBL] [Abstract][Full Text] [Related]
18. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
19. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
20. [Proton pump inhibitors according to need. Always for heartburn].
Labenz J
MMW Fortschr Med; 2002 Jun; 144(23):34-7. PubMed ID: 12119901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
